The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer.
G. Thomas Budd
Consultant or Advisory Role - Amgen
William E. Barlow
No relevant relationships to disclose
Halle C. F. Moore
No relevant relationships to disclose
Timothy J. Hobday
No relevant relationships to disclose
James A. Stewart
No relevant relationships to disclose
Claudine Isaacs
No relevant relationships to disclose
Muhammad Salim
No relevant relationships to disclose
Jonathan K. Cho
No relevant relationships to disclose
Kristine Rinn
No relevant relationships to disclose
Kathy S. Albain
No relevant relationships to disclose
Helen K. Chew
No relevant relationships to disclose
Gary Von Burton
No relevant relationships to disclose
Timothy David Moore
Honoraria - Amgen
Gordan Srkalovic
No relevant relationships to disclose
Bradley Alexander McGregor
No relevant relationships to disclose
Lawrence E. Flaherty
No relevant relationships to disclose
Robert B. Livingston
No relevant relationships to disclose
Danika Lew
No relevant relationships to disclose
Julie Gralow
Research Funding - Amgen; Novartis; Roche; Roche/Genentech
Gabriel N. Hortobagyi
No relevant relationships to disclose